Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
Cowen sees hope for ECYT amid acquisition refocus; H.C.
It’s a very rewarding trading day for investors in Endocyte, Inc. (NASDAQ:ECYT) with shares up nearly 90%, making the stock Wall Street’s bull …
In a research report released Friday, Cowen analyst Boris Peaker downgraded shares of Endocyte, Inc. (NASDAQ:ECYT) from Outperform to Market Perform, after the drug maker …
Endocyte, Inc. (NASDAQ:ECYT) announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted …
Endocyte, Inc. (NASDAQ:ECYT) announced their plan to collaborate with Seattle Children’s Research Institute and Dr.
Endocyte, Inc. (NASDAQ:ECYT) presented poster updates on its two lead clinical programs at the ESMO 2016 Congress, being held in Copenhagen, Denmark October 7-11, …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results …